Market Place
Sourcing Support
Mediar, Lilly License Antibody for Idiopathic Pulmonary Fibrosis
10 Jan 2025 //
PR NEWSWIRE
Mediar Therapeutics Initiates Second Clinical Program
07 Aug 2024 //
PR NEWSWIRE
Mediar begins patient dosing in US FDA approved phase 1 trial of MTX-463
07 May 2024 //
PHARMABIZ
Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs
25 Oct 2023 //
PR NEWSWIRE
Mediar gets a spark from Pfizer’s Ignite program
25 Oct 2023 //
FIERCE BIOTECH
With $105M and Big Pharma backing, Mediar takes aim at fibrosis
15 Mar 2023 //
FIERCE BIOTECH
Pfizer-backed Mediar Therapeutics ropes in another Big Pharma investor
05 Dec 2022 //
ENDPTS
Simon Sturge Joins Mediar Therapeutics as Executive Chairman
15 Sep 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.